Matthias Alder - 21 Mar 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Executive Officer, Director
Signature
/s/ Matthias Alder
Issuer symbol
GANX
Transactions as of
21 Mar 2024
Net transactions value
$0
Form type
4
Filing time
25 Mar 2024, 21:30:11 UTC
Previous filing
22 Dec 2023
Next filing
28 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +370,000 $0.000000 370,000 21 Mar 2024 Common Stock 370,000 $4.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on March 21, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.